Featured

Deep and durable T cell responses after oncolytic viral therapy in glioblastoma

In a recent clinical trial, patients with glioblastoma (GBM) were treated with a single dose of an oHSV-1-based oncolytic viral therapy, rQNestin34.5v.2 (CAN-3110, linoserpaturev), in which expression of the viral ICP34.5 gene was controlled by the...

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Becilli, Metzler, Bracaglia et al. treated 8 children with severe/refractory autoimmune diseases (AD) with one dose of CD19 CAR T cells to reset the dysregulated immune system. CAR T cells were succes...

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

Focused on key challenges of CD19 CAR T cell therapy, such as on-target/off-tumor healthy B cell depletion and antigen-negative escape and relapse, Cohen, Bochi-Layec and Lemoine et al. developed CAR...

Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma

Peng, Yang, Antonopoulou, et al. found that in human PDAC, high expression of GATA6 correlated with increased MHC-I expression, immune cell infiltration, and interactions with CD8+ T cells. In murine ...

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial

Based on the randomized phase 3 LungTIME-C01 trial, Huang et al. reported that early time of day (ToD) treatment (before 3 pm) for the first 4 doses improved anti-PD-1 efficacy compared with late ToD ...

See all for this week

Previous Digests

Good things come in threes: results from clinical trials to improve checkpoint blockade

February 11, 2026

Immune checkpoint blockade (ICB) has become a staple in the treatment of numerous cancers, but its efficacy could still be improved. Recently, three separate clinical trials explored strategies to improve ICB in the clinic. In one study, Duttagupta, Messaoudene...

BACH2 orchestrates T cell differentiation and can be used to optimize cellular immunotherapies

February 4, 2026

Adoptive T cell transfer (ACT) and CAR-T treatment strategies are limited in their efficacy against solid tumors, as chronic antigen exposure induces exhaustion phenotypes, with reduced proliferation and effector function, limited persistence, and reduced therapeutic efficacy as consequences. Three...

Breaking bad macrophages through remodeling with armored CAR-T

January 28, 2026

CAR T cell efficacy is limited in solid tumors due to their highly immunosuppressive tumor microenvironment (TME), which is partially and often significantly driven by tumor-associated macrophages (TAMs). Various therapies are in development to remodel the TME to improve...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials